W.L. Gore & Associates, Inc. v. C.R. Bard, Inc.

761 F. Supp. 376, 19 U.S.P.Q. 2d (BNA) 1621, 1991 U.S. Dist. LEXIS 4898
CourtDistrict Court, D. New Jersey
DecidedApril 9, 1991
DocketCiv. 84-729
StatusPublished
Cited by2 cases

This text of 761 F. Supp. 376 (W.L. Gore & Associates, Inc. v. C.R. Bard, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
W.L. Gore & Associates, Inc. v. C.R. Bard, Inc., 761 F. Supp. 376, 19 U.S.P.Q. 2d (BNA) 1621, 1991 U.S. Dist. LEXIS 4898 (D.N.J. 1991).

Opinion

OPINION

SAROKIN, District Judge.

Before the court is defendant’s motion to modify a permanent injunction entered into with the consent of both parties.

Introduction

A settlement of litigation involves an analysis by the parties which invariably takes into account the issues of fact and the existing state of the applicable law, and each party measures its settlement position and offers against its likelihood of success. In resolving the matter the parties compromise their respective demands and defenses and arrive at a negotiated agreement. The question presented by this matter is whether a settlement resulting in a consent judgment predicated upon the then state of the law should be modified, if the law upon which it was based is modified or abolished.

Although the cases which have dealt with this issue recognize the court’s power to grant such modification, whether the decree is the result of consent or judicial determination, the considerations for the exercise of the court’s discretion should not be the same for both. An injunction, which by its very nature has prospective application, is easily modified if the law upon which the judicial determination has been made no longer prevails. If the court prohibits conduct because Congress has prohibited it, the lifting of that statutory *378 prohibition, in most instances, should cause the court to lift its prohibition.

However, when the parties have bargained for the prohibition, and the existing law is only part of the consideration for the bargain, then exercise of the court’s discretion should be more limited, notwithstanding a change in the law.

Modification would be required if the new law prohibited what the old law and consent decree allowed. But modification is not necessarily required where the new law allows what the old law and the consent decree prohibited. The parties can impose limitations by agreement which exceed those imposed by the government, provided the limitations themselves are not illegal.

The restrictions imposed upon the defendant in this matter were the result of the negotiations and in particular, a substantial reduction in plaintiffs’ claims for damages. Defendant should not be able to modify that part of the bargain which is detrimental to its interests, but hold plaintiffs to their surrender of rights and claims. Plaintiffs could have bargained for and received the restriction which defendant now seeks to strike whether the law so provided or not. Plaintiffs should not be required to surrender the benefit of its bargain because of a change in the law, no more than plaintiffs would be able to claim additional monies of defendant if it discovered that its damages were far greater than it had anticipated or knew at the time of the settlement. So long as continuation of the challenged provision is neither illegal nor against public policy, the agreement of the parties should be upheld notwithstanding the subsequent change in the law — absent extreme hardship or prejudice not reasonably anticipated at the time of the agreement. No such hardship or prejudice has been presented here, and thus the motion to modify the decree shall be denied for the reasons herein expressed.

Factual Background

In 1980 plaintiffs W.L. Gore & Associates, Inc. and Gore Enterprise Holdings (collectively “Gore”) received a patent, Patent No. 4,187,390, for “Porous Products and Process Therefor.” 1 In 1982, defendant C.R. Bard, Inc. (“Bard”) received FDA approval to market its medical device known as a vascular prosthesis made from a form of plastic called polytetrafluoroethy-lene (PTFE). Gore sells a similar product under its GORE-TEX brand. In February 1984, Gore sued defendant for infringement of the Gore patent.

After discovery, the parties settled the suit. Bard consented to pay Gore $600,000 and to entry of a Final Judgment and Injunction on Consent, dated April 12, 1984. In the injunction, Bard consented to both the validity of the Gore patent and infringement thereof by Bard’s manufacture, use, and sale of expanded PTFE vascular grafts. Defendant’s Schechter Declaration, Exhibit B at If 2, 3. The injunction provided that Bard is enjoined from “infringing or actively inducing infringement” of plaintiffs’ patent, “including, without limitation, the manufacture and/or use and/or sale and/or the promotion of sale and/or use of products heretofore identified as ‘Bard PTFE Reinforced Expanded PTFE Vascular Prosthesis’ or as ‘Bard Blood Access PTFE Vascular Prosthesis.’ ” Id. at 114. Gore’s patent expires in April, 1993. Plaintiffs’ Declaration of James R. Phelps at K 2.

In 1984, at the time the parties entered into the consent injunction, it was considered patent infringement to make, use or sell a patented product for the limited purpose of testing and investigation related to FDA approval, in anticipation of the expiration of a patent. Roche Products, Inc. v. Bolar Pharmaceutical Co., 733 F.2d 858 (Fed.Cir.), cert. den., 469 U.S. 856, 105 S.Ct. 183, 83 L.Ed.2d 117 (1984), interpreting 35 U.S.C. § 271(a). In response to *379 the Roche case, on September 24, 1984, Congress amended the statute at issue:

(e)(1) It shall not be an act of infringement to make, use, or sell a patented invention ... solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products.
(e)(3) In any action for patent infringement brought under this section, no in-junctive or other relief may be granted which would prohibit the making, using, or selling of a patented invention under paragraph (1).

Added to Title 35, U.S.C., by The Drug Price Competition and Patent Term Restoration Act of 1984, Pub.L. No. 98-417, 98 Stat. 1585, 1603. In 1990 the Supreme Court ruled that this statutory provision applies not only to medical devices, but also to drugs. Eli Lilly and Co. v. Medtronic, Inc., — U.S. —, 110 S.Ct. 2683, 2689, 110 L.Ed.2d 605 (1990). The Court noted that because, under the pre-existing law, it would be a violation of the patent for a competitor to do the necessary work to obtain FDA approval before the patent expired, the patentee’s effective monopoly over the product was extended beyond the expiration date of the patent.

On the basis of this change in the statute and the Court’s interpretation of it, Bard now seeks to modify the remaining prospective application of the consent injunction in this case. Plaintiffs oppose defendant’s motion to modify, arguing that Bard has not made a sufficient showing of “extreme and unexpected hardship” to warrant a modification of the consent decree, and also that application of the statutory provision in this ease would violate Gore’s constitutional rights.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
761 F. Supp. 376, 19 U.S.P.Q. 2d (BNA) 1621, 1991 U.S. Dist. LEXIS 4898, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wl-gore-associates-inc-v-cr-bard-inc-njd-1991.